2026 Q2 - tulosraportti
60 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,70%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 166 | - | - | ||
| 2 500 | - | - | ||
| 334 | - | - | ||
| 14 | - | - | ||
| 526 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenRemember it is free to trade in week 41 Think we see 245-265 range this week
·12 t sitten• Saxo Bank sees low point as an advantage: A strategist from Saxo Bank has stated that the current low expectations and the sharp price drop could end up turning into a major advantage for Novo in 2027, as the bar for positive surprises is now set low. • Buying opportunity after price drop: Several independent financial houses, including analyses on platforms like Seeking Alpha, highlight that Novo's strong free cash flows and an attractive dividend yield of around 4.6% make the stock a solid and "cheap" long-term investment after the recent price correction. • Strategic acquisition potential: Analysts view positively Novo's two recent multi-billion agreements at the end of September with Swedish Nanexa and Chinese Hengrui Pharma. This is assessed as a strong move to future-proof the pipeline against competition from Eli Lilly. The average of the analysts' price targets is currently around 293-307 kr., indicating that they see a noticeable upward potential from the current price level.
Price targets are completely useless. Bank analysts' price targets often follow the stock price down and are no guarantee that the market has underestimated Novo. Low bar != regained trust. The fact that expectations have been beaten down makes it easier to surprise positively, but the market's trust in the growth story still needs to be rebuilt. Cheap can get cheaper. History shows this too. Lower multiples and higher dividends do not automatically make the stock attractive if earnings estimates continue downward. Pipeline acquisitions do not solve the problem now. HRS-1596 is only in phase 1. The new agreements can create great value long-term, but change very little for earnings in the coming years. The Lilly problem persists. The crucial factor is still whether Novo can defend market share and growth against Eli Lilly, not how many new pipeline agreements the company announces. Novo doesn't need, in my world, any more positive analyst quotes. The stock needs execution, stabilized estimates, and documentation that growth can accelerate again. Only then do I truly believe the market's trust will turn. I own Novo myself.
·14 t sitten · MuokattuIf anyone went into the weekend feeling downcast - then check out investor, bon vivant and optimist Clem Chambers reporting from Monaco and talking about market downturns every time there is a quarter-end and many other things. The video is not Novo-relevant, but highly relevant to the mindset required when investing: https://www.youtube.com/watch?v=znItwNiAfhoWhy would anyone head into the weekend dejected? Markets saw massive gains over the last trading days, and particularly on Friday there were big increases across the board.
·15 t sitten · MuokattuComical Ali writes in a comment that she is telling the truth 😂 When it was at 400kr it could only go up, when it was at 338 it could only go up, it will never go below 300kr anymore etc, now it is at 248 kr not for fun she is called Comical Ali
There are now quite good studies indicating that semaglutide (Wegovy) can reduce alcohol consumption and alcohol cravings👍
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
60 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,70%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenRemember it is free to trade in week 41 Think we see 245-265 range this week
- ·12 t sitten• Saxo Bank sees low point as an advantage: A strategist from Saxo Bank has stated that the current low expectations and the sharp price drop could end up turning into a major advantage for Novo in 2027, as the bar for positive surprises is now set low. • Buying opportunity after price drop: Several independent financial houses, including analyses on platforms like Seeking Alpha, highlight that Novo's strong free cash flows and an attractive dividend yield of around 4.6% make the stock a solid and "cheap" long-term investment after the recent price correction. • Strategic acquisition potential: Analysts view positively Novo's two recent multi-billion agreements at the end of September with Swedish Nanexa and Chinese Hengrui Pharma. This is assessed as a strong move to future-proof the pipeline against competition from Eli Lilly. The average of the analysts' price targets is currently around 293-307 kr., indicating that they see a noticeable upward potential from the current price level.Price targets are completely useless. Bank analysts' price targets often follow the stock price down and are no guarantee that the market has underestimated Novo. Low bar != regained trust. The fact that expectations have been beaten down makes it easier to surprise positively, but the market's trust in the growth story still needs to be rebuilt. Cheap can get cheaper. History shows this too. Lower multiples and higher dividends do not automatically make the stock attractive if earnings estimates continue downward. Pipeline acquisitions do not solve the problem now. HRS-1596 is only in phase 1. The new agreements can create great value long-term, but change very little for earnings in the coming years. The Lilly problem persists. The crucial factor is still whether Novo can defend market share and growth against Eli Lilly, not how many new pipeline agreements the company announces. Novo doesn't need, in my world, any more positive analyst quotes. The stock needs execution, stabilized estimates, and documentation that growth can accelerate again. Only then do I truly believe the market's trust will turn. I own Novo myself.
- ·14 t sitten · MuokattuIf anyone went into the weekend feeling downcast - then check out investor, bon vivant and optimist Clem Chambers reporting from Monaco and talking about market downturns every time there is a quarter-end and many other things. The video is not Novo-relevant, but highly relevant to the mindset required when investing: https://www.youtube.com/watch?v=znItwNiAfhoWhy would anyone head into the weekend dejected? Markets saw massive gains over the last trading days, and particularly on Friday there were big increases across the board.
- ·15 t sitten · MuokattuComical Ali writes in a comment that she is telling the truth 😂 When it was at 400kr it could only go up, when it was at 338 it could only go up, it will never go below 300kr anymore etc, now it is at 248 kr not for fun she is called Comical AliThere are now quite good studies indicating that semaglutide (Wegovy) can reduce alcohol consumption and alcohol cravings👍
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 166 | - | - | ||
| 2 500 | - | - | ||
| 334 | - | - | ||
| 14 | - | - | ||
| 526 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
60 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,70%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenRemember it is free to trade in week 41 Think we see 245-265 range this week
- ·12 t sitten• Saxo Bank sees low point as an advantage: A strategist from Saxo Bank has stated that the current low expectations and the sharp price drop could end up turning into a major advantage for Novo in 2027, as the bar for positive surprises is now set low. • Buying opportunity after price drop: Several independent financial houses, including analyses on platforms like Seeking Alpha, highlight that Novo's strong free cash flows and an attractive dividend yield of around 4.6% make the stock a solid and "cheap" long-term investment after the recent price correction. • Strategic acquisition potential: Analysts view positively Novo's two recent multi-billion agreements at the end of September with Swedish Nanexa and Chinese Hengrui Pharma. This is assessed as a strong move to future-proof the pipeline against competition from Eli Lilly. The average of the analysts' price targets is currently around 293-307 kr., indicating that they see a noticeable upward potential from the current price level.Price targets are completely useless. Bank analysts' price targets often follow the stock price down and are no guarantee that the market has underestimated Novo. Low bar != regained trust. The fact that expectations have been beaten down makes it easier to surprise positively, but the market's trust in the growth story still needs to be rebuilt. Cheap can get cheaper. History shows this too. Lower multiples and higher dividends do not automatically make the stock attractive if earnings estimates continue downward. Pipeline acquisitions do not solve the problem now. HRS-1596 is only in phase 1. The new agreements can create great value long-term, but change very little for earnings in the coming years. The Lilly problem persists. The crucial factor is still whether Novo can defend market share and growth against Eli Lilly, not how many new pipeline agreements the company announces. Novo doesn't need, in my world, any more positive analyst quotes. The stock needs execution, stabilized estimates, and documentation that growth can accelerate again. Only then do I truly believe the market's trust will turn. I own Novo myself.
- ·14 t sitten · MuokattuIf anyone went into the weekend feeling downcast - then check out investor, bon vivant and optimist Clem Chambers reporting from Monaco and talking about market downturns every time there is a quarter-end and many other things. The video is not Novo-relevant, but highly relevant to the mindset required when investing: https://www.youtube.com/watch?v=znItwNiAfhoWhy would anyone head into the weekend dejected? Markets saw massive gains over the last trading days, and particularly on Friday there were big increases across the board.
- ·15 t sitten · MuokattuComical Ali writes in a comment that she is telling the truth 😂 When it was at 400kr it could only go up, when it was at 338 it could only go up, it will never go below 300kr anymore etc, now it is at 248 kr not for fun she is called Comical AliThere are now quite good studies indicating that semaglutide (Wegovy) can reduce alcohol consumption and alcohol cravings👍
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 166 | - | - | ||
| 2 500 | - | - | ||
| 334 | - | - | ||
| 14 | - | - | ||
| 526 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt